Vaughan Nelson Investment Management L.P. Sells 449,440 Shares of Bruker Corporation $BRKR

Vaughan Nelson Investment Management L.P. trimmed its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 21.5% during the 4th quarter, HoldingsChannel.com reports. The firm owned 1,640,715 shares of the medical research company’s stock after selling 449,440 shares during the quarter. Vaughan Nelson Investment Management L.P.’s holdings in Bruker were worth $77,294,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of BRKR. Allworth Financial LP raised its stake in shares of Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the last quarter. Spire Wealth Management boosted its position in shares of Bruker by 85.3% during the third quarter. Spire Wealth Management now owns 1,445 shares of the medical research company’s stock valued at $47,000 after buying an additional 665 shares during the last quarter. Jones Financial Companies Lllp increased its holdings in Bruker by 79.7% in the 3rd quarter. Jones Financial Companies Lllp now owns 2,773 shares of the medical research company’s stock worth $86,000 after buying an additional 1,230 shares in the last quarter. Elevation Point Wealth Partners LLC purchased a new position in Bruker in the 2nd quarter worth about $87,000. Finally, EverSource Wealth Advisors LLC raised its position in Bruker by 51.5% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,770 shares of the medical research company’s stock worth $114,000 after buying an additional 942 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on BRKR shares. Bank of America raised their price target on shares of Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a report on Monday, December 15th. JPMorgan Chase & Co. increased their price objective on shares of Bruker from $50.00 to $55.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Wells Fargo & Company raised their target price on shares of Bruker from $48.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, December 15th. UBS Group reaffirmed a “neutral” rating and issued a $49.00 target price on shares of Bruker in a research report on Friday, February 13th. Finally, Zacks Research upgraded shares of Bruker from a “strong sell” rating to a “hold” rating in a research note on Monday, December 8th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Bruker has a consensus rating of “Hold” and an average target price of $49.77.

Bruker Trading Up 1.7%

Bruker stock opened at $34.31 on Tuesday. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $56.22. The company has a market cap of $5.22 billion, a P/E ratio of -228.73, a P/E/G ratio of 2.02 and a beta of 1.19. The company has a quick ratio of 0.87, a current ratio of 1.73 and a debt-to-equity ratio of 0.75. The business has a 50-day simple moving average of $39.77 and a two-hundred day simple moving average of $41.31.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing the consensus estimate of $0.65 by ($0.06). The business had revenue of $977.20 million during the quarter, compared to the consensus estimate of $964.61 million. Bruker had a positive return on equity of 13.56% and a negative net margin of 0.25%.Bruker’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter last year, the company earned $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts predict that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 23rd will be given a $0.05 dividend. The ex-dividend date is Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker’s dividend payout ratio (DPR) is presently -133.33%.

Insider Buying and Selling at Bruker

In other news, VP Mark Munch sold 7,000 shares of the business’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the completion of the sale, the vice president owned 128,443 shares of the company’s stock, valued at $7,064,365. The trade was a 5.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last 90 days, insiders have sold 11,000 shares of company stock worth $554,280. Company insiders own 27.30% of the company’s stock.

Bruker Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.